Advertisment

The Critical Role of Genetic Testing in Colorectal Cancer: A Comprehensive Look

author-image
Medriva Correspondents
New Update
NULL

The Critical Role of Genetic Testing in Colorectal Cancer: A Comprehensive Look

Advertisment

Colorectal cancer, an often lethal malady, is a growing concern, especially among individuals under the age of 50. A significant contributor to its development is genetic predisposition, making genetic testing an essential aspect of colorectal cancer care. Dr. David Johnson, renowned professor of medicine and chief of gastroenterology at Eastern Virginia Medical School, presents compelling insights into this critical subject.

Advertisment

Understanding Lynch Syndrome

Lynch syndrome is a genetic condition that significantly increases the risk of developing colorectal cancer. It is estimated that 1 million people in the United States live with Lynch syndrome, yet the majority remain unaware of their status. This lack of awareness underscores the crucial role gastroenterologists can play in identifying and testing for this condition.

Genetic Testing: A Key Tool

Advertisment

Over the past few decades, genetic testing has evolved remarkably. It now facilitates the detection of abnormalities that predispose individuals to familial adenomatous polyposis and Lynch syndrome. Microsatellite instability (MSI) evaluation and immunohistochemistry (IHC) testing are paramount methods for defining and measuring Lynch syndrome through mismatch repair frequency deficiency.

The Significance of the PREMM5 Model

In the fight against this form of hereditary colon cancer, the PREMM5 model has proven its worth. This predictive model for mismatch repair includes genes that qualify for Lynch syndrome, making it a vital tool for cancer prevention through proband testing.

Advertisment

The Challenge of Genetic Testing

Nonetheless, genetic testing is not without its challenges. Factors like IHC staining reliability, the potential for false normal results, and the importance of germline susceptibility testing for Lynch syndrome, are all important considerations.

The Rise of Early-Onset Colorectal Cancer

Advertisment

Early-onset colorectal cancer (EOCRC), which is diagnosed before the age of 50, accounts for about 10% of colon cancers and 15-20% of rectal cancers. Alarmingly, the incidence of EOCRC has been rising in higher-income countries. This group of patients is more likely to have a genetic predisposition, with up to 16-25% having a hereditary genetic syndrome.

Updated NCCN Guidelines and Reflex Testing

The updated NCCN guidelines recommend reflex testing on all colon cancers in patients under the age of 50. This approach aids in early detection and treatment, thereby increasing the chances of a positive outcome.

Advertisment

Emerging Technologies in Genetic Testing

Emerging technologies such as machine learning are also being used to enhance colorectal cancer testing. For instance, a machine learning-assisted detection platform with multi-target components is being developed for colorectal cancer and colorectal adenoma screening. This non-invasive, economical, and effective risk stratification platform holds promise for auxiliary screening in clinical practice.

At-Home Genetic Tests

Advertisment

At-home genetic tests have also emerged as a viable option for detecting major health risks like cancer by analyzing gene variants. However, understanding and managing the results require professional guidance, underscoring the need for consultations with doctors or genetic counselors.

The Importance of Germline Testing

Dr. Johnson emphasizes that germline testing should be a standard of care for all patients. Gastroenterologists must initiate discussions and offer genetic panels to patients, thereby playing a proactive role in the fight against colorectal cancer.

In conclusion, genetic testing, despite its challenges, is a critical tool in the diagnosis and treatment of colorectal cancer. It requires continuous advancement and wider adoption to ensure early detection and improved outcomes for patients at risk.

Advertisment
Chat with Dr. Medriva !